TrialLeukemia2019

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Daniel A Pollyea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.